University of Liège, CIRM, Laboratory of Pharmacognosy, Liège, Belgium.
Phytomedicine. 2012 Feb 15;19(3-4):278-83. doi: 10.1016/j.phymed.2011.09.072. Epub 2011 Oct 19.
As part of our continuing research for anticancer compounds from the Walloon Region forest, EtOAc extract from Carpinus betulus leaves was phytochemically studied, leading to the bioguided isolation of pheophorbide a, which is responsible of anticancer properties of C. betulus young leaves. This compound was identified using nuclear magnetic resonance and mass spectrophotometric data and comparison with a commercial standard. Evaluation of the growth inhibitory activities of pheophorbide a using MTT colorimetric assay and phase-contrast microscopy in various human cancer cell lines confirmed the photoactivable properties of this compound. Our research showed, for the first time, the presence of pheophorbide a, a chlorophyll derived compound, which we quantified in high quantities in young leaves of C. betulus. This is in contrast with the literature which generally describes pheophorbide a as a catabolic product of chlorophyll, then preferentially present in old leaves.
作为我们从瓦隆地区森林中寻找抗癌化合物的持续研究的一部分，对欧洲山毛榉叶的 EtOAc 提取物进行了植物化学研究，导致生物导向分离出了原卟啉 a，它是欧洲山毛榉幼叶抗癌特性的原因。该化合物通过核磁共振和质谱分光光度数据以及与商业标准的比较进行了鉴定。MTT 比色法和相差显微镜在各种人癌细胞系中评估原卟啉 a 的生长抑制活性，证实了该化合物的光激活特性。我们的研究首次表明，存在原卟啉 a，这是一种叶绿素衍生的化合物，我们在欧洲山毛榉的幼叶中大量定量检测到了它。这与文献形成了对比，文献通常将原卟啉 a 描述为叶绿素的分解产物，然后优先存在于老叶中。
